{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:49:37Z","timestamp":1790520577972,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T00:00:00Z","timestamp":1414972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jamda.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T10:05:04Z","timestamp":1416477904000},"page":"866-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Treatment of Cachexia: An Overview of Recent Developments"],"prefix":"10.1016","volume":"15","author":[{"given":"Stephan","family":"von Haehling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2014.09.007_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13539-013-0124-8","article-title":"Cachexia vs obesity: Where is the real unmet clinical need?","volume":"4","author":"von Haehling","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: Impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: Facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: A new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jamda.2014.09.007_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13539-013-0105-y","article-title":"Cachexia as a major public health problem: Frequent, costly, and deadly","volume":"4","author":"Farkas","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jamda.2011.04.014","article-title":"Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: An international consensus","volume":"12","author":"Morley","year":"2011","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2014.09.007_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13539-012-0089-z","article-title":"From muscle wasting to sarcopenia and myopenia: Update 2012","volume":"3","author":"von Haehling","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s13539-014-0156-8","article-title":"Sarcopenia: Describing rather than defining a condition","author":"Alchin","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-011-0025-7","article-title":"Myopenia\u2014a new universal term for muscle wasting","volume":"2","author":"Fearon","year":"2011","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-014-0135-0","article-title":"Muscle wasting disease: A proposal for a new disease classification","volume":"5","author":"Anker","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13539-011-0052-4","article-title":"Sarcopenia and cachexia: The adaptations of negative regulators of skeletal muscle mass","volume":"3","author":"Sakuma","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13539-014-0146-x","article-title":"Osteosarcopenic obesity: The role of bone, muscle, and fat on health","volume":"5","author":"Ormsbee","year":"2014","journal-title":"Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-012-0062-x","article-title":"Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia","volume":"3","author":"Pedroso","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-011-0041-7","article-title":"Molecular control of neuromuscular junction development","volume":"3","author":"Ferraro","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13539-014-0149-7","article-title":"Are we closer to having drugs to treat muscle wasting disease?","volume":"5","author":"Morley","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jamda.2012.08.001","article-title":"Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: A systematic review","volume":"14","author":"Malafarina","year":"2013","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2014.09.007_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: A systematic overview","volume":"121","author":"von Haehling","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jamda.2014.09.007_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s13539-014-0139-9","article-title":"Attenuation of muscle wasting in murine C2\/C12 myotubes by epigallocatechin-3-gallate","author":"Mirza","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13539-011-0044-4","article-title":"Ursodeoxycholic acid treatment in a rat model of cancer cachexia","volume":"3","author":"Tschirner","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0101-7","article-title":"Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia","volume":"4","author":"Der-Torossian","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13539-012-0064-8","article-title":"European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS). Is there a genetic cause of appetite loss? An explorative study in 1,853 cancer patients","volume":"3","author":"Solheim","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fphys.2014.00088","article-title":"Pancreatic cancer cachexia: A review of mechanisms and therapeutics","volume":"5","author":"Tan","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.jamda.2014.09.007_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13539-012-0082-6","article-title":"Anorexia\/cachexia of chronic diseases: A role for the TGF-\u03b2 family cytokine MIC-1\/GDF15","volume":"3","author":"Tsai","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jamda.2013.02.004","article-title":"Body weight, anorexia, and undernutrition in older people","volume":"14","author":"Soenen","year":"2013","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2014.09.007_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clnu.2013.01.004","article-title":"A\u00a0new look at an old drug for the treatment of cancer cachexia: Megestrol acetate","volume":"32","author":"Argil\u00e9s","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jamda.2014.09.007_bib27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000346446","article-title":"Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide","volume":"58","author":"Wen","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jamda.2014.09.007_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0017-7","article-title":"L-carnitine and cancer cachexia: Clinical and experimental aspects","volume":"2","author":"Silv\u00e9rio","year":"2011","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine\u00a0+ celecoxib \u00b1 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jamda.2014.09.007_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1475-2891-11-52","article-title":"L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)\u2014A randomized multicentre trial","volume":"11","author":"Kraft","year":"2012","journal-title":"Nutr J"},{"key":"10.1016\/j.jamda.2014.09.007_bib32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/pbc.24828","article-title":"A\u00a0randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and\/or cancer therapy","volume":"61","author":"Cuvelier","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-8993(00)02031-X","article-title":"Melatonin reversal of DOI-induced hypophagia in rats: Possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis","volume":"860","author":"Raghavendra","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.jamda.2014.09.007_bib34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2012.43.6766","article-title":"Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo-controlled trial","volume":"31","author":"Del Fabbro","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jamda.2014.09.007_bib35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting IL-1\u03b1 in refractory cancers: An open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jamda.2014.09.007_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","article-title":"Clinical pharmacology of thalidomide","volume":"57","author":"Eriksson","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2014.09.007_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sampaio","year":"1993","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jamda.2014.09.007_bib38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","article-title":"The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: Results of a double-blind placebo-controlled randomized study","volume":"15","author":"Yennurajalingam","year":"2012","journal-title":"J\u00a0Palliat Care"},{"key":"10.1016\/j.jamda.2014.09.007_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jpainsymman.2011.03.007","article-title":"A\u00a0phase II dose titration study of thalidomide for cancer-associated anorexia","volume":"43","author":"Davis","year":"2012","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jamda.2014.09.007_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0026-6","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13539-013-0115-9","article-title":"Anti-inflammatory and anti-oxidative nutrition in hypoalbuminemic dialysis patients (AIONID) study: Results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial","volume":"4","author":"Rattanasompattikul","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib42","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.biocel.2013.04.025","article-title":"Muscle wasting in heart failure: An overview","volume":"45","author":"von Haehling","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jamda.2014.09.007_bib43","first-page":"80","article-title":"Endocrine and metabolic activities of a recently isolated peptide hormone ghrelin, an endogenous ligand of the growth hormone secretagogue receptor","volume":"38","author":"Jarkovska","year":"2004","journal-title":"Endocr Regul"},{"key":"10.1016\/j.jamda.2014.09.007_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-012-0074-6","article-title":"Molecular and cellular mechanisms of skeletal muscle atrophy: An update","volume":"3","author":"Fanzani","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.21690","article-title":"Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients","volume":"106","author":"Wolf","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13539-012-0060-z","article-title":"Effect of sexual dimorphism on muscle strength in cachexia","volume":"3","author":"Norman","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-012-0065-7","article-title":"Hypogonadism in male cancer patients","volume":"3","author":"Burney","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13539-012-0085-3","article-title":"Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model","volume":"4","author":"Lenk","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-013-0103-0","article-title":"Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: The rationale and design of the Body Size in Stroke Study (BoSSS)","volume":"4","author":"Knops","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib51","first-page":"3949","article-title":"Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals","volume":"29","author":"Legakis","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jamda.2014.09.007_bib52","first-page":"281","article-title":"The behaviour of the peptides leptin and ghrelin, PYY, NPY, CART and MSH in gastric cancer patients","volume":"3","author":"Barao","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s13539-012-0090-6","article-title":"Research on cachexia, sarcopenia and skeletal muscle in cardiology","volume":"3","author":"Coats","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib54","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","article-title":"Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure","volume":"110","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2014.09.007_bib55","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1378\/chest.128.3.1187","article-title":"Treatment of cachexia with ghrelin in patients with COPD","volume":"128","author":"Nagaya","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jamda.2014.09.007_bib56","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1200\/jco.2007.25.18_suppl.9133","article-title":"A\u00a0phase II, randomized, placebo-controlled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer-cachexia [abstract]","volume":"25","author":"Garcia","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jamda.2014.09.007_bib57","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jamda.2014.09.007_bib58","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","article-title":"Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: A randomised, placebo-controlled, double-blind, double-crossover study","volume":"98","author":"Strasser","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib59","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1681\/ASN.2005010039","article-title":"Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial","volume":"16","author":"Wynne","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jamda.2014.09.007_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ki.2009.114","article-title":"Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment","volume":"76","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jamda.2014.09.007_bib61","doi-asserted-by":"crossref","first-page":"e35708","DOI":"10.1371\/journal.pone.0035708","article-title":"Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"7","author":"Miki","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jamda.2014.09.007_bib62","first-page":"295","article-title":"Efficacy and safety results from a phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients","volume":"4","author":"Temel","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib63","first-page":"295","article-title":"Anamorelin HCl for the treatment of anorexia-cachexia in lung cancer: Study design and baseline characteristics of patients in the phase III clinical trial ROMANA 2 (HT-ANAM-302)","volume":"4","author":"Abernethy","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib65","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","article-title":"Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: A double-blind, placebo-controlled, randomized study","volume":"54","author":"Caminiti","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2014.09.007_bib66","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jacc.2010.03.090","article-title":"Testosterone therapy in women with chronic heart failure: A pilot double-blind, randomized, placebo-controlled study","volume":"56","author":"Iellamo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2014.09.007_bib67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","article-title":"Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)","volume":"34","author":"F\u00fclster","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jamda.2014.09.007_bib68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.96.2.526","article-title":"Hormonal changes and catabolic\/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia","volume":"96","author":"Anker","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2014.09.007_bib69","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.2009.639","article-title":"Circulating estradiol and mortality in men with systolic chronic heart failure","volume":"301","author":"Jankowska","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2014.09.007_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13539-012-0061-y","article-title":"Recent developments in the treatment of cachexia: Highlights from the 6th Cachexia Conference","volume":"3","author":"Ebner","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.maturitas.2013.03.014","article-title":"Mechanism and novel therapeutic approaches to wasting in chronic disease","volume":"75","author":"Ebner","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.jamda.2014.09.007_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib73","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13539-013-0114-x","article-title":"Type VI collagen turnover-related peptides\u2014novel serological biomarkers of muscle mass and anabolic response to loading in young men","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib74","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: A double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jamda.2014.09.007_bib75","first-page":"35","article-title":"Enobosarm, a selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced non-small cell lung cancer patients in two pivotal, international Phase 3 trials","volume":"5","author":"Crawford","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib76","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00520-013-1832-5","article-title":"Testosterone replacement for fatigue in\u00a0hypogonadal ambulatory males with advanced cancer: A preliminary double-blind placebo-controlled trial","volume":"21","author":"Del Fabbro","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jamda.2014.09.007_bib77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13539-011-0046-2","volume":"24","author":"Stewart Coats","year":"2011","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib78","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-013-0125-7","article-title":"The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats","volume":"52","author":"P\u00f6tsch","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib79","first-page":"35","article-title":"Beta-blocker for the treatment of cancer cachexia: are they all equal?","volume":"5","author":"Palus","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib80","first-page":"35","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer (ACT-ONE): randomised, double-blind, placebo-controlled, international multi-centre phase II study","volume":"5","author":"Stewart Coats","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jamda.2014.09.007_bib81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13539-014-0136-z","article-title":"Highlights from the 7th Cachexia Conference: Muscle wasting pathophysiological detection and novel treatment strategies","volume":"5","author":"Ebner","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152586101400588X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152586101400588X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T01:43:27Z","timestamp":1598492607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152586101400588X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S152586101400588X"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2014.09.007","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Cachexia: An Overview of Recent Developments","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AMDA \u2013 The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}